GM-2505 is under clinical development by Gilgamesh Pharmaceuticals and currently in Phase I for Psychiatric Disorders. According to GlobalData, Phase I drugs for Psychiatric Disorders have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GM-2505’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GM-2505 is under development for the treatment of depression and other psychiatric disorders. The therapeutic candidate is a short acting psychoactive compound which acts by targeting 5-hydroxytryptamine receptor 2A (HTR2A) and is being developed based on AI-powered ENKIDU platform.
Gilgamesh Pharmaceuticals overview
Gilgamesh is a serious mental health science focused, preclinical biotechnology company. The company has a disciplined focus on developing innovative new chemical entities (NCE’s) leveraging a combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise.
For a complete picture of GM-2505’s drug-specific PTSR and LoA scores, buy the report here.